Business Wire

CLIC-INNOVATION

27.8.2024 13:08:28 CEST | Business Wire | Press release

Share
CLIC Innovation: REMHub Project Develops a Digital Innovation Hub for Rare Earth Elements and Rare Magnets

Rare earth elements and rare magnets play a crucial role in advancing the green energy transition and achieving the goals of the European Green Deal. While the EU currently relies heavily on imports from a few countries— with approximately 90% of REEs* coming from outside the EU—this presents an opportunity to develop European expertise and forge strategic partnerships in rare earth metals processing. Strengthening these capabilities within Europe is key to reaching our ambitious targets. Additionally, while challenges remain in REEs recycling, with current rates being less than 5% and some extraction processes needing sustainability improvements, these challenges also present a significant potential for innovation and growth. As demand for REEs increases, driven by their use in electric vehicles, wind turbine motors, and electrolysers for clean hydrogen, there is a tremendous opportunity to enhance recycling efforts and establish more sustainable extraction processes within the EU.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240827785891/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

CLIC Innovation: REMHub Project Develops a Digital Innovation Hub for Rare Earth Elements and Rare Magnets (Copyright (c) 2024 Phawat/Shutterstock)

Project targets and development areas

REMHub will develop, test and pilot novel technologies for the exploration and primary production of rare earth elements and for recovering them from side streams to enhance supply security of REEs and rare magnets in the EU. In addition, the project will develop Re-X (Recycle, Reuse, refurbishment and repurposing) technologies for rare earths and valuable metals from end-of-life products as well as electric machine design for easier permanent magnet recycling. The project will also identify and engage relevant stakeholders to develop REE value chains in the EU. The innovation hub will ensure that the novel technologies developed in the project will be commercialized and offered as services via digital platform in the future.

The project’s multi-stakeholder communication and dissemination efforts are designed to actively involve and engage the public and various stakeholders, fostering trust and raising awareness about the importance of REEs. These activities also aim to build essential capacities within the EU. The hub focuses on transformative material sourcing for REEs and REE magnets, including innovations in traceability, digital twinning, and digital passports. Our project partners span the entire REE value chain, from mineral exploration and processing to metal production, magnet manufacturing, and recycling.

The project is committed to a safe and sustainable by design (SSbD) framework, embracing a Re-X approach that prioritizes recycling, reuse, refurbishment, and repurposing, while integrating features for easy dismantling and circularity. REMHub is set to significantly enhance the security of REE supply in the EU. With the support of our digital innovation hub, it will accelerate the development of technologies and services, enabling faster and easier market entry. By the conclusion of the project, future organizations will find it much easier to access sustainably developed REE expert services within the EU.

Project in a nutshell

The project will commence at the beginning of October and last for four years. The project consortium consists of 24 partners from six countries: Finland, Estonia, Spain, Ireland, Slovenia, and Italy. The project preparation and consortium coordination were led by the Finnish organization CLIC Innovation, which also serves as the project coordinator. The estimated total volume of the project is 18 million euros, of which 16 million euros is EU funding. The EU Horizon "resilient value chains" funding instrument supports European sustainable development value chain projects with financing from the European Commission.

* source: https://scrreen.eu/wp-content/uploads/2023/08/SCRREEN2_factsheets_REE-EUROSTAT.pdf

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240827785891/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release

Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye